| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
ORIGINAL RESEARCH COMMUNICATION |
1 From the National Center for Environmental Health, Centers for Disease Control and Prevention, Atlanta, GA
See corresponding editorial on page 279.
 |
ABSTRACT |
|---|
 TOP ABSTRACT INTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Objective: The objective was to determine the effect of folic acid fortification on concentrations of serum and red blood cell (RBC) folate, serum vitamin B-12, and plasma total homocysteine (tHcy) and methylmalonic acid (MMA) in the US population.
Design: Blood was collected from a nationally representative sample of 
7300 participants aged 
3 y in the National Health and Nutrition Examination Survey (NHANES) during 1999–2000 and was analyzed for these B vitamin–status indicators. The results were compared with findings from the prefortification survey NHANES III (1988–1994).
Results: The reference ranges (5th–95th percentiles) were 13.1–74.3 nmol/L for serum folate, 347–1167 nmol/L for RBC folate, and 179–738 pmol/L for serum vitamin B-12. For plasma tHcy and MMA, the reference ranges for serum vitamin B-12–replete participants with normal serum creatinine concentrations were 3.2–10.7 µmol/L and 60–210 nmol/L, respectively. The prevalence of low serum folate concentrations (<6.8 nmol/L) decreased from 16% before to 0.5% after fortification. In elderly persons, the prevalence of high serum folate concentrations (>45.3 nmol/L) increased from 7% before to 38% after fortification; 3% had marginally low serum vitamin B-12 concentrations (<148 pmol/L) and 7% had elevated plasma MMA concentrations (>370 nmol/L). Seventy-eight percent of the US population had plasma tHcy concentrations <9 µmol/L.
Conclusions: Every segment of the US population appears to benefit from folic acid fortification. Continued monitoring of B vitamin concentrations in the US population is warranted.
Key Words: Nutrition survey • age • sex • race • ethnic groups • National Health and Nutrition Examination Survey • NHANES
|
INTRODUCTION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Folate deficiency is already an established risk factor for the development of certain types of cancer in the general population (5). A chronic deficiency of folate in the diet can cause anemia (1), but low concentrations of serum folate and vitamin B-12 and elevated concentrations of plasma tHcy have also been associated with psychiatric disorders (6); the development of dementia, Alzheimer disease, and cognitive dysfunction (7–10); a decline in physical function (11); osteoporosis and hip fractures in the elderly (12, 13); and an increased risk of carotid artery stenosis (14). Two recent meta-analyses concluded that a 25% reduction of plasma tHcy is associated with an 11–16% decrease in risk of ischemic heart disease and a 19–22% decrease in risk of stroke (15, 16). Clinical trials have shown that folic acid supplementation decreases the risk of neural tube birth defects (17, 18). In 1998, the Food and Drug Administration required the fortification of enriched cereal-grain products with folic acid at a concentration of 140 µg/100 g cereal grain (19).
Although severe vitamin B-12 deficiency causes anemia, hematologic signs are not always present, and hematologic and neurologic abnormalities are inversely correlated in vitamin B-12 deficiency (4). Some evidence suggests that excess supplemental folate intake may precipitate or exacerbate the neurologic damage of vitamin B-12 deficiency; a summary of such human case reports has been compiled by the US Institute of Medicine (20). Because elderly people have lower serum vitamin B-12 concentrations than do younger people (21–23), they may be particularly susceptible to the most serious sequelae because consequences may be irreversible when vitamin B-12 deficiency goes untreated.
Since 1998, a few studies have shown significant improvements in folate status in selected populations (24–27). The National Health and Nutrition Examination Survey (NHANES) 1999–2000 is the first and only source of nationally representative data on the B vitamins and their biochemically related products after the introduction of folic acid fortification. This report describes the concentrations of and presents the reference data for serum and red blood cell (RBC) folate, serum vitamin B-12, and plasma tHcy and MMA in the US population aged 3 y. The changes in B vitamin concentrations between the prefortification and postfortification periods are discussed.
|
SUBJECTS AND METHODS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
60 y (28). Blood for B vitamin measurements was collected from participants 4 y of age.
In 1999 NHANES became a continuous survey (29, 30). Although each year constitutes a national probability sample, 2 y of data are necessary to have adequate sample sizes for subgroup analyses. The procedures for selecting participants and for conducting interviews and examinations in NHANES 1999–2000 were similar to those used in NHANES III. The NHANES 1999–2000 survey sample comprised 9965 participants. Of these, 93% were interviewed in their homes and underwent physical examination in mobile examination centers. Mexican American and non-Hispanic black persons, all adolescents (ages 12–19 y), and all persons aged 60 y were oversampled to improve estimates in these groups. All respondents gave their informed consent, and the NHANES 1999–2000 protocol was reviewed and approved by the NCHS NHANES Institutional Review Board. Blood for B vitamin measurements was collected from participants aged 3 y.
Fasting status and supplement use
To assess the extent to which blood concentrations of folate and vitamin B-12 are affected after a meal is eaten, the NHANES 1999–2000 data were analyzed by fasting status. The respondents were asked to fast for either 10–16 h or for 6 h, depending on whether their appointment at the mobile examination center was in the morning or in the afternoon or evening. Before the phlebotomy was performed, the respondents were asked when they last ate or drank and the number of hours that they had fasted was calculated. Fasting status was categorized as fasting 9 h or <9 h (this category included those who reported having just eaten). The respondents were asked separately about their use of vitamin or mineral supplements in the past 24 h. Therefore, when analyzing fasting status, use of supplements in the past 24 h was controlled for by selecting only those persons who reported not taking a supplement. Approximately one-half of the participants (54.3%) had fasted 9h before phlebotomy. These 2 fasting categories had no measurable effect on serum or RBC folate, serum vitamin B-12, or plasma tHcy and MMA concentrations. All further data analyses were conducted without the exclusion of supplement users or participants who fasted <9 h before phlebotomy.
Biochemical measurement of serum and RBC folate, serum vitamin B-12, and plasma tHcy and MMA concentrations
Depending on the age of the participant, data were collected on demographics, physical function, health condition, lifestyle behaviors, biochemical measurements of blood and urine, body measurements, and dietary intake. Blood was collected by venipuncture in mobile examination centers and processed under controlled, constant environmental conditions according to standard protocols (31).
The NHANES Laboratory of the CDC analyzed serum and RBC folate for both phases of NHANES III, serum vitamin B-12 for phase II of NHANES III (1991–1994), and all 5 indicators for NHANES 1999–2000 (32). Serum and RBC folate and serum vitamin B-12 were analyzed by using a commercially available radioprotein binding assay kit (Quantaphase I during phase I of NHANES III and Quantaphase II during phase II of NHANES III and during NHANES 1999–2000; Bio-Rad Laboratories, Hercules, CA). The serum and RBC folate assay measures primarily 5-methyltetrahydrofolic acid and folic acid but is considered to estimate total folate in serum and whole blood. RBC folate was measured after lysis of 1 part of whole blood with 10 parts of 1% ascorbic acid solution (performed in the mobile examination center) and one freeze-thaw cycle to ensure cleavage of polyglutamyl folates to monoglutamates by the action of the endogenous plasma deconjugase. The serum vitamin B-12 assay measures cyanocobalamin in its circulating bound and free forms. Long-term CVs for the NHANES 1999–2000 period were 4–7% for serum folate at 5.2–30.0 nmol/L, 4–6% for RBC folate at 143–1119 nmol/L, and 3–6% for serum vitamin B-12 at 281–1160 pmol/L.
Measurements of tHcy and MMA changed from NHANES III to NHANES 1999–2000 because different laboratories conducted the analyses, and different matrices and methods were used. Because optimally prepared EDTA-treated plasma was not available during NHANES III, tHcy and MMA were analyzed in surplus serum from phase II of NHANES III (1991–1994) at the US Department of Agriculture (USDA) Human Nutrition Research Center on Aging. tHcy was measured by HPLC with fluorometric detection (33); MMA was measured by gas chromatography–mass spectrometry by using solid-phase extraction and derivatization with cyclohexanol (34) for persons 60 y of age and for a subset of adults 30–39 y of age. For NHANES 1999–2000, EDTA-treated whole blood was processed within 30 min of collection to avoid an artificial increase in tHcy, and plasma was immediately frozen at –70 °C. Plasma tHcy was analyzed by using a commercially available fluorescence polarization immunoassay kit (Abbott Laboratories, Abbott Park, IL) on the Abbott IMx analyzer (35). Plasma MMA was measured by gas chromatography–mass spectrometry with cyclohexanol derivatization (36). A 10% subset of all samples was also analyzed for plasma tHcy by HPLC with fluorometric detection and cystamine as internal standard (37, 38). Both assays measure tHcy in plasma, which is the sum of reduced, oxidized, and protein-bound homocysteine. The comparison of the 2 tHcy methods for the NHANES 1999–2000 period gave the following results: Pearson's correlation coefficient, 0.98; Deming regression (Abbott), 0.97 x HPLC – 0.2; absolute bias (95% confidence limit), –0.4 µmol/L (–0.4, –0.3); and relative bias, –5%. Long-term CVs for the 2-y period were 3–6% for plasma tHcy by Abbott at 6.7–29.0 µmol/L, 4–7% for plasma tHcy by HPLC at 6.7–29.5 µmol/L, and 4–11% for plasma MMA at 120–10400 nmol/L. A formal tHcy method comparison was conducted between the HPLC methods used at the CDC NHANES and the USDA laboratories, and the results were as follows: Pearson's correlation coefficient, 0.97; Deming regression, USDA HPLC = 0.82 x CDC HPLC + 0.9; absolute bias (95% confidence limit), –0.6 µ mol/L (–0.5, –0.8); relative bias, –6% (39). We also determined that under the conditions applied to sample processing during NHANES III, tHcy in serum was overestimated compared with tHcy in optimally prepared EDTA-treated plasma by an average of 10% (39). Because of changes in matrix and methods, a direct comparison of the tHcy results obtained with the 2 surveys is inappropriate (39). No formal MMA method comparison was conducted between the gas chromatography–mass spectrometry methods used at the CDC NHANES and the USDA laboratory, which precludes direct comparison of the MMA results between these 2 surveys.
Statistical analysis
The statistical analyses were performed with SAS for WINDOWS (version 8.0; SAS Institute Inc, Cary, NC) in conjunction with SUDAAN statistical software (version 8.0.2; 40). Data were weighted to account for survey design (unequal probability of selection, adjustments for oversampling of certain populations) and nonresponse. On the basis of questionnaire self-assignment, the participants were categorized into 3 racial-ethnic groups: Mexican Americans, non-Hispanic blacks, and non-Hispanic whites. No separate data analysis was performed for persons from other ethnic groups (n = 876). Because of significant metabolic changes in B vitamins and their biochemically related products during pregnancy, we excluded pregnant women from all data analysis. Supplement users were not evaluated separately in our data analysis. In the comparison of estimates, only statistically significant differences at a significance level of 
= 0.01 are reported. We consistently used this more stringent significance level rather than using = 0.05 and adjusting the level based on the number of comparisons made; the maximum number of groups that we compared was 5.
This report presents population means, SEMs, and selected percentiles for serum and RBC folate, serum vitamin B-12, and plasma tHcy and MMA that were representative of the noninstitutionalized civilian US population for NHANES 1999–2000. As recommended by NCHS, a Taylor series variance estimation method appropriate for complex survey data was used to estimate SEMs (29). Because the distributions of these biomarkers were skewed, logarithmic transformations of the distributions were used for the statistical analyses. We age-adjusted means by using SUDAAN PROC DESCRIPT standardization statements and the following 2000 Census population proportions: 20–39 y, 0.3966; 40–59 y, 0.3718; and 60 y, 0.2316 (30). We tested for sex-by-race (Table 1
), sex-by-age (Figure 1), and race-by-age interactions using an analysis of variance model that included age (6 age groups), sex (males and females), racial-ethnic group (Mexican Americans, non-Hispanic blacks, and non-Hispanic whites) and the abovementioned interaction terms. If the interaction term was not significant (P 0.01) we only reported the means by subgroup without performing subgroup analysis to test for significant differences. We tested for main effects of sex, race, and age using the same analysis of variance model as for the interaction testing. We tested for significant differences between males and females or between racial-ethnic groups by using census age-adjusted geometric means and a 2-tailed, 2-group t test with 14 df (Table 1). We tested for significant differences between age groups (using age group 20–39 y as a reference) or between males and females (within one age group) by using geometric means and a 2-tailed 2-group t test with 14 df in a model that included age, sex, race, and sex-by-age interaction (Figure 1).
|
|
1.4 for our sample, strata with <220 individuals gave imprecise estimates of the 5th and 95th percentiles. We used the 5th and 95th percentiles of the entire population, except for pregnant women, to estimate the population reference ranges for serum and RBC folate and serum vitamin B-12. To establish population reference ranges (5th and 95th percentiles) for plasma tHcy and MMA, we created a reference sample in which we included only persons who were vitamin B-12 replete (serum vitamin B-12 concentrations above the 50th percentile; 41) and excluded persons with serum creatinine concentrations indicative of impaired renal function (ie, >133 µmol/L for men and >115 µmol/L for women)—the principal cause of elevated plasma tHcy and MMA concentrations for reasons other than suboptimal B vitamin status. Serum and RBC folate concentrations were not considered exclusionary for preparing the tHcy and MMA reference sample because the entire population was considered to be folate replete (serum folate concentration >6.8 nmol/L).
To assess the effect of fortification on blood folate and vitamin B-12 concentrations, we compared NHANES III data with NHANES 1999–2000 data. We applied the same procedure as described above to calculate age-adjusted means, but, as recommended by the NCHS (30), we used different proportions derived from the 2000 census population: 20–39 y, 0.4332; 40–59 y, 0.4062; and 60 y, 0.1606. We tested for significant differences between prefortification and postfortification values for various subgroups by using age-specific or age-adjusted geometric means and a 2-tailed, 2-group t test. To compare the prevalence estimates from NHANES III with those from NHANES 1999–2000, we used the SE and df associated with each estimate to compute the SE and df associated with the difference. We then performed a 2-tailed, 2-group t test.
|
RESULTS |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
3 y, respectively. The study population was 51% male and included 5% children aged 3–5 y, 41% children and adolescents (6–19 y), 34% adults (20–59 y), and 21% elderly persons (60 y), which reflected the oversampling in the survey as described earlier. To allow a comparison with previous reports (23, 41-44), detailed tables containing age-specific means and distributions of B vitamin and metabolite concentrations for participants by sex are provided online; see Tables S1-S4 under "Supplemental data" in the current online issue at www.ajcn.org. Table S1 contains data for all racial-ethnic groups combined, whereas Tables S2-S4 contain data for individual racial-ethnic groups (Mexican Americans, non-Hispanic blacks, and non-Hispanic whites).
The reference ranges (5th–95th percentiles) for the B vitamins for the US population after the introduction of folic acid fortification were 13.1–74.3 nmol/L for serum folate, 347–1167 nmol/L for RBC folate, and 179–738 pmol/L for serum vitamin B-12. The references ranges for the metabolites for the part of the US population that was vitamin B-12 replete and did not exhibit elevated serum creatinine concentrations were 3.2–10.7 µmol/L for plasma tHcy and 60–210 nmol/L for MMA.
The age-adjusted geometric mean concentrations for adults aged 20 y were 30.5 nmol/L for serum folate, 646 nmol/L for RBC folate, 340 pmol/L for serum vitamin B-12, 7.7 µmol/L for plasma tHcy, and 137 nmol/L for MMA (Table 1
). We found a significant sex-by-race interaction for serum vitamin B-12 but not for serum and RBC folate (P = 0.345 and P = 0.699, respectively) or plasma tHcy and MMA (P = 0.228 and P = 0.137, respectively). We found a significant main effect of sex for plasma MMA, and significant main effects of race for serum and RBC folate and for plasma tHcy and MMA. On the basis of census age-adjusted data, males had lower serum folate and higher plasma tHcy and MMA concentrations than did females, but RBC folate concentrations were not significantly different between the sexes (P = 0.043). Non-Hispanic whites had higher serum and RBC folate concentrations than did non-Hispanic blacks and Mexican Americans. Mexican Americans had lower plasma tHcy concentrations than did non-Hispanic whites and non-Hispanic blacks, but the difference between non-Hispanic whites and non-Hispanic blacks was not significant (P = 0.088). Non-Hispanic whites had higher plasma MMA concentrations than did non-Hispanic blacks and Mexican Americans, but the difference between non-Hispanic blacks and Mexican Americans was not significant (P = 0.444). The lack of a significant sex-by-race interaction for serum and RBC folate and plasma tHcy and MMA precluded further subgroup analysis. The presence of a significant sex-by-race interaction for serum vitamin B-12 precluded main-effect comparisons between males and females and between racial-ethnic groups. However, a subgroup analysis showed that non-Hispanic white males had lower serum vitamin B-12 concentrations than did non-Hispanic black and Mexican American males, but the difference between non-Hispanic black and Mexican American males was not significant (P = 0.026). The same pattern applied for females (P = 0.597).
We found a significant sex-by-age interaction for serum folate and plasma tHcy but not for RBC folate (P = 0.021), serum vitamin B-12 (P = 0.020), and plasma MMA (P = 0.026) (Figure 1). We found significant main effects of age for serum vitamin B-12, RBC folate, and plasma MMA. Serum and RBC folate concentrations tended to first decrease with age, then increase after age 40 y (Figure 1). Compared with the age group 20–39 y (reference), all age groups of males had higher serum folate concentrations and all but the 40–59 y age group of females had higher serum folate concentrations (P = 0.068). Sex differences were shown in the 20–39 y and 60 y age groups. Serum vitamin B-12 concentrations tended to decrease with age (Figure 1). Plasma tHcy concentrations increased steadily with age (Figure 1). Compared with the 20–39 y age group (reference), all age groups of both sexes had significantly different plasma tHcy concentrations. Sex differences were found for all age groups 12–19 y. Plasma MMA concentrations tended to be higher in elderly people (Figure 1).
Comparison between NHANES III and NHANES 1999–2000 for serum and RBC folate and serum vitamin B-12
From NHANES III to NHANES 1999–2000, the US population shifted to much higher serum folate [median (95% CI): from 12.5 (11.8, 12.9) to 32.2 (30.1, 33.8) nmol/L] and RBC folate [from 392 (381, 406) to 625 (600, 650) nmol/L] concentrations and to slightly higher serum vitamin B-12 concentrations [344 (336, 350) and 359 (352, 367) pmol/L] (Figure 2). Serum and RBC folate concentrations showed large increases and serum vitamin B-12 concentrations showed slight increases in each sex and racial-ethnic subgroup from before to after fortification, except for vitamin B-12 in non-Hispanic blacks (P = 0.181; Table 2). Serum and RBC folate concentrations also showed large increases in each age group. Serum vitamin B-12 increased only in elderly persons (P = 0.574 for the 
5 y age group, P = 0.124 for the 6–11 y age group, P = 0.288 for the 12–19 y age group, P = 0.185 for the 20–39 y age group, and P = 0.015 for the 40–59 y age group; Table 2).
|
|
The Life Sciences Research Office panel defined low RBC folate concentrations as <317 nmol/L (46). The prevalence of low RBC folate concentrations decreased from 31% in NHANES III to 3% in NHANES 1999–2000 for the US population and from 38% to 5% for women of childbearing age. Although the overall prevalence of low RBC folate concentrations decreased significantly after the introduction of folic acid fortification, pronounced ethnic differences remained in folate status: 2% of Mexican American, 4% of non-Hispanic white, and 11% of non-Hispanic black women of childbearing age had RBC folate concentrations <317 nmol/L.
We arbitrarily defined high serum folate concentrations as >45.3 nmol/L, which reflected the upper end of the Bio-Rad Quantaphase II calibration range, beyond which samples need to be diluted and reanalyzed to obtain a valid result. The prevalence of high serum folate concentrations increased from 7% in NHANES III to 43% in NHANES 1999–2000 for children aged 5 y and from 7% to 38% for elderly persons.
Serum vitamin B-12 concentrations <74 pmol/L usually suggest vitamin B-12 deficiency (45); <1% of the entire population and of elderly persons had serum vitamin B-12 concentrations <74 pmol/L in NHANES III and in NHANES 1999–2000. Serum vitamin B-12 concentrations <148 pmol/L are considered moderately low, but do not necessarily indicate vitamin B-12 deficiency (45). The prevalence of moderately low serum vitamin B-12 concentrations in elderly persons was somewhat lower in NHANES 1999–2000 (3%) than in NHANES III (5%); the difference was significant. At a cutoff of 185 pmol/L, 7% of elderly persons had moderately low serum vitamin B-12 concentrations in NHANES 1999–2000 compared with 13% in NHANES III; this difference was also significant.
Prevalence of elevated plasma tHcy and MMA concentrations
No generally agreed on cutoff exists for elevated plasma tHcy, but 13 µmol/L has sometimes been used to define elevated tHcy concentrations (13). Five percent of the US population, 18% of elderly men and 11% of elderly women, had plasma tHcy concentrations >13 µmol/L in NHANES 1999–2000. Ubbink (47) suggested that a tHcy concentration of 9 µmol/L is desirable should the outcome of controlled clinical trials show that a lowering of plasma tHcy concentrations reduces the incidence of cardiovascular disease. In NHANES 1999–2000, 78% of the US population (72% of males and 85% of females) and 50% of elderly persons (40% of elderly males and 60% of elderly females) had plasma tHcy concentrations 9 µ mol/L. A generally agreed on cutoff for elevated plasma MMA is 370 nmol/L (48, 49). Two percent of the US population and 7% of elderly persons had elevated MMA concentrations.
|
DISCUSSION |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Since folic acid fortification began in the United States in 1998, the US population shifted to significantly higher serum and RBC folate concentrations. We observed increases across all subgroups of age, sex, or race-ethnicity. Adolescents and adults have experienced the biggest relative increase, children aged 5 y the smallest increase, and elderly persons an intermediate increase. Without distinguishing between supplement and nonsupplement users, serum and RBC folate increased by 18–23 and 204–272 nmol/L across all age groups.
These findings are consistent with earlier findings from NHANES 1999–2000 that folate status has improved significantly in women of childbearing age, the target group for the folic acid fortification (27), as well as reports of improved folate status in selected nonrepresentative subsets of the US population. In the Framingham population, mean serum folate concentrations among nonusers of B vitamin supplements increased from 11 nmol/L before to 23 nmol/L after fortification, and the prevalence of low serum folate concentrations (<6.8 nmol/L) decreased from 22% to 2% (13); RBC folate concentrations increased by 38% (25). Median serum folate concentrations in samples submitted to Kaiser Permanente's Southern California Endocrinology Laboratory during 1994–1998 steadily increased from 28.6 nmol/L before to 42.4 nmol/L after fortification (26). After the introduction of folic acid fortification in Canada, Ray et al (53) reported from a retrospective cross-sectional study geometric mean serum and RBC folate concentrations of 34.5 and 957 nmol/L, respectively; these concentrations were higher than expected and even higher than concentrations found in the United States. In 2 later reports, the authors found increases of 64% in serum folate in a nonrepresentative sample of elderly women in Ontario and British Columbia (54) and 41% in RBC folate in a nonrepresentative sample of women of childbearing age in Ontario (55). In Chile, after the mandatory fortification of wheat flour with folic acid, targeted to increase daily folate consumption of women of childbearing age by 400 µg, serum and RBC folate concentrations in a representative population sample increased 284% and 144%, respectively (56). The increase in RBC folate concentrations in the US population after fortification also seems compatible with the increase shown by Daly et al (57) in a double-blind, randomized, placebo-controlled trial of women of childbearing age who were supplemented with 200 µg folic acid/d.
Although the increase in serum and RBC folate concentrations in the US population after fortification in our analysis is consistent with other reports on nonrepresentative subpopulations, the increase is still higher than was expected from the 70–130-µg/d increase predicted by the US fortification program (58). The discrepancy may be due to unknown sampling biases between NHANES III and NHANES 1999–2000, changes in vitamin supplementation, or an imprecise ability to predict folate intake from blood folate concentrations. Because of the stable results for long-term quality control of the Bio-Rad assay between the 2 surveys, changes in laboratory techniques are unlikely to account for the shift in folate concentrations. Another possible explanation for the higher than expected folate concentrations could be a higher than expected daily intake of folic acid due to either the underestimation of food quantities eaten or overage added to cereal-grain products in the process of fortification. Rader et al (59) reported significant excess fortification in a survey of recently fortified products. Furthermore, the spectrum of voluntarily fortified snack foods seems to undergo constant growth and change.
The US Institute of Medicine has reviewed all potential adverse effects of high doses of folic acid and found that the only basis for tolerable upper intake levels (UL) was the potential masking of vitamin B-12 deficiency (20). The UL for adults was set to 1 mg folate/d from fortified food or supplements, the UL for children was set to 300–800 µg/d, depending on age. Although the serum folate concentration that should be considered excessively high and its health implications are not known, folic acid ingested in quantities >266 µg in one meal can appear unmetabolized in serum (60). In NHANES III, 3% of the US population, 7% of children aged 5 y, and 8% of elderly persons had high serum folate concentrations (>45.3 nmol/L). In NHANES 1999–2000, after folic acid fortification began, 23% of the US population, 43% of children aged 5 y, and 38% of elderly persons reached this putatively high serum folate concentration. The issue of potential adverse effects of excess folate in persons with untreated vitamin B-12 deficiency remains unsolved. Mills et al (61) reported that in persons with low serum vitamin B-12 concentrations (<258 pmol/L) examined during 1992–2000 at the Veterans Affairs Medical Center in Washington, DC, the proportion of persons without anemia did not increase significantly from the prefortification period (39.2%) to the period of optional fortification (45.5%) or in the postfortification period (37.6%). We are unaware of any epidemiologic evidence of an increased risk of masked vitamin B-12 insufficiency or related disease after folic acid fortification, but clinically recognized vitamin B-12 insufficiency may be uncommon. Indeed, <1% of the US population had low serum vitamin B-12 concentrations (<74 pmol/L) that suggested vitamin B-12 deficiency, and <5% had moderately low serum vitamin B-12 concentrations (<148 pmol/L). Interestingly, serum vitamin B-12 concentrations increased slightly but significantly in the US population between the prefortification and postfortification periods. This increase was limited mainly to elderly persons. Whether the increase may be due to unknown sampling biases between the 2 surveys, changes in vitamin supplementation, or a higher intake of vitamin B-12–rich foods is not known.
A direct comparison of plasma tHcy concentrations between NHANES 1999–2000 and NHANES III is not possible because of differences in the methods and matrices of the 2 surveys. However, tHcy concentrations after fortification appeared lower than in NHANES III (41, 42, 44). When we chose a cutoff of 13 µmol/L, we found that 14% of elderly persons had elevated plasma tHcy concentrations. This corresponds well with a 10% prevalence of elevated tHcy after folic acid fortification compared with a prevalence of 20% before fortification in the Framingham population (24). What seems even more important, though, is that nearly 80% of the US population had achieved a plasma tHcy concentration <9 µmol/L, which is considered a desirable concentration (47).
We have presented the first nationally representative US population reference ranges for the B vitamins serum and RBC folate, serum vitamin B-12, and their biochemically related products plasma tHcy and MMA after the mandatory folic acid fortification of cereal-grain products was introduced in the United States in 1998. The fortification program has increased concentrations of serum and RBC folate in the entire population and virtually eliminated folate deficiency. Vitamin B-12 concentrations in elderly persons appear to be slightly higher. Plasma tHcy concentrations appear to be lower after fortification, and 80% of the population has achieved desirable concentrations. Nutritional monitoring for folate status remains exceedingly important, not only for women of childbearing age but also for children and persons of all ages. Nutritional monitoring for vitamin B-12 status, particularly in elderly persons, is similarly important.
|
ACKNOWLEDGMENTS |
|---|
EWG and EJS were involved in the design of NHANES. EWG and CMP supervised the laboratory work. SPC and CMP performed the data analysis. CMP wrote the initial draft of the manuscript. JO provided significant advice on the data analysis and interpretation. All authors contributed to the final manuscript. None of the authors declared any personal or financial conflict of interest.
|
REFERENCES |
|---|
|
TOPABSTRACTINTRODUCTIONSUBJECTS AND METHODSRESULTSDISCUSSIONREFERENCES |
|---|
Related articles in AJCN:
This article has been cited by other articles:
|
|
 |
|
  G. M. Lindzon, A. Medline, K.-J. Sohn, F. Depeint, R. Croxford, and Y.-I. Kim Effect of folic acid supplementation on the progression of colorectal aberrant crypt foci Carcinogenesis, September 1, 2009; 30(9): 1536 - 1543. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. J. Piyathilake, M. Macaluso, R. D. Alvarez, W. C. Bell, D. C. Heimburger, and E. E. Partridge Lower Risk of Cervical Intraepithelial Neoplasia in Women with High Plasma Folate and Sufficient Vitamin B12 in the Post-Folic Acid Fortification Era Cancer Prevention Research, July 1, 2009; 2(7): 658 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Q. Yang, R. M. Bostick, J.M. Friedman, and W. D. Flanders Serum Folate and Cancer Mortality Among U.S. Adults: Findings from the Third National Health and Nutritional Examination Survey Linked Mortality File Cancer Epidemiol. Biomarkers Prev., May 1, 2009; 18(5): 1439 - 1447. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Marian and G. Sacks Micronutrients and Older Adults Nutr Clin Pract, April 1, 2009; 24(2): 179 - 195. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M. Molloy, P. N. Kirke, J. F. Troendle, H. Burke, M. Sutton, L. C. Brody, J. M. Scott, and J. L. Mills Maternal Vitamin B12 Status and Risk of Neural Tube Defects in a Population With High Neural Tube Defect Prevalence and No Folic Acid Fortification Pediatrics, March 1, 2009; 123(3): 917 - 923. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Lemos, I. Kathmann, E. Giovannetti, J. A.M. Belien, G. L. Scheffer, C. Calhau, G. Jansen, and G. J. Peters Cellular folate status modulates the expression of BCRP and MRP multidrug transporters in cancer cell lines from different origins Mol. Cancer Ther., March 1, 2009; 8(3): 655 - 664. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. H Allen How common is vitamin B-12 deficiency? Am. J. Clinical Nutrition, February 1, 2009; 89(2): 693S - 696S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Selhub, M. S. Morris, P. F Jacques, and I. H Rosenberg Folate-vitamin B-12 interaction in relation to cognitive impairment, anemia, and biochemical indicators of vitamin B-12 deficiency Am. J. Clinical Nutrition, February 1, 2009; 89(2): 702S - 706S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Green Is it time for vitamin B-12 fortification? What are the questions? Am. J. Clinical Nutrition, February 1, 2009; 89(2): 712S - 716S. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Kerr, B. Livingstone, C. J. Bates, I. Bradbury, J. M. Scott, M. Ward, K. Pentieva, M. A. Mansoor, and H. McNulty Folate, Related B Vitamins, and Homocysteine in Childhood and Adolescence: Potential Implications for Disease Risk in Later Life Pediatrics, February 1, 2009; 123(2): 627 - 635. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. C. Tangney, Y. Tang, D. A. Evans, and M. C. Morris Biochemical indicators of vitamin B12 and folate insufficiency and cognitive decline Neurology, January 27, 2009; 72(4): 361 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Y. Tsai, C. M. Loria, J. Cao, Y. Kim, D. Siscovick, P. J. Schreiner, and N. Q. Hanson Clinical Utility of Genotyping the 677C>T Variant of Methylenetetrahydrofolate Reductase in Humans Is Decreased in the Post-Folic Acid Fortification Era J. Nutr., January 1, 2009; 139(1): 33 - 37. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. P. Leamon, J. A. Reddy, R. Dorton, A. Bloomfield, K. Emsweller, N. Parker, and E. Westrick Impact of High and Low Folate Diets on Tissue Folate Receptor Levels and Antitumor Responses Toward Folate-Drug Conjugates J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 918 - 925. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B. Dowd and A. E Aiello Did national folic acid fortification reduce socioeconomic and racial disparities in folate status in the US? Int. J. Epidemiol., October 1, 2008; 37(5): 1059 - 1066. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y.-I. Kim Folic Acid Supplementation and Cancer Risk: Point Cancer Epidemiol. Biomarkers Prev., September 1, 2008; 17(9): 2220 - 2225. [Full Text] [PDF]
|
|
|
|
|
|
H. Refsum and A D. Smith Are we ready for mandatory fortification with vitamin B-12? Am. J. Clinical Nutrition, August 1, 2008; 88(2): 253 - 254. [Full Text] [PDF]
|
|
|
|
|
|
L. Hao, Q.-H. Yang, Z. Li, L. B Bailey, J.-H. Zhu, D. J Hu, B.-L. Zhang, J D. Erickson, L. Zhang, J. Gindler, et al. Folate status and homocysteine response to folic acid doses and withdrawal among young Chinese women in a large-scale randomized double-blind trial Am. J. Clinical Nutrition, August 1, 2008; 88(2): 448 - 457. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Nguyen, R. Grajeda, P. Melgar, J. Marcinkevage, R. Flores, and R. Martorell Weekly May Be as Efficacious as Daily Folic Acid Supplementation in Improving Folate Status and Lowering Serum Homocysteine Concentrations in Guatemalan Women J. Nutr., August 1, 2008; 138(8): 1491 - 1498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-H. Yang, L. D Botto, M. Gallagher, J. Friedman, C. L Sanders, D. Koontz, S. Nikolova, J D. Erickson, and K. Steinberg Prevalence and effects of gene-gene and gene-nutrient interactions on serum folate and serum total homocysteine concentrations in the United States: findings from the third National Health and Nutrition Examination Survey DNA Bank Am. J. Clinical Nutrition, July 1, 2008; 88(1): 232 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. G. Luebeck, S. H. Moolgavkar, A. Y. Liu, A. Boynton, and C. M. Ulrich Does Folic Acid Supplementation Prevent or Promote Colorectal Cancer? Results from Model-Based Predictions Cancer Epidemiol. Biomarkers Prev., June 1, 2008; 17(6): 1360 - 1367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. M. Ueland and S. Hustad Homocysteine and Folate Status in an Era of Folic Acid Fortification: Balancing Benefits, Risks, and B-vitamins Clin. Chem., May 1, 2008; 54(5): 779 - 781. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Pfeiffer, J. D. Osterloh, J. Kennedy-Stephenson, M. F. Picciano, E. A. Yetley, J. I. Rader, and C. L. Johnson Trends in Circulating Concentrations of Total Homocysteine among US Adolescents and Adults: Findings from the 1991-1994 and 1999-2004 National Health and Nutrition Examination Surveys Clin. Chem., May 1, 2008; 54(5): 801 - 813. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Hung, C. M. Abratte, W. Wang, R. Li, D. J. Moriarty, and M. A. Caudill Ethnicity and Folate Influence Choline Status in Young Women Consuming Controlled Nutrient Intakes J. Am. Coll. Nutr., April 1, 2008; 27(2): 253 - 259. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Kotsopoulos, K.-J. Sohn, and Y.-I. Kim Postweaning Dietary Folate Deficiency Provided through Childhood to Puberty Permanently Increases Genomic DNA Methylation in Adult Rat Liver J. Nutr., April 1, 2008; 138(4): 703 - 709. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D. Smith, Y.-I. Kim, and H. Refsum Is folic acid good for everyone? Am. J. Clinical Nutrition, March 1, 2008; 87(3): 517 - 533. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. H. Lichtenstein, H. Rasmussen, W. W. Yu, S. R. Epstein, and R. M. Russell Modified MyPyramid for Older Adults J. Nutr., January 1, 2008; 138(1): 5 - 11. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Hoey, H. McNulty, N. Askin, A. Dunne, M. Ward, K. Pentieva, J. Strain, A. M Molloy, C. A Flynn, and J. M Scott Effect of a voluntary food fortification policy on folate, related B vitamin status, and homocysteine in healthy adults Am. J. Clinical Nutrition, November 1, 2007; 86(5): 1405 - 1413. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. K. Kant and B. I. Graubard Ethnicity Is an Independent Correlate of Biomarkers of Micronutrient Intake and Status in American Adults J. Nutr., November 1, 2007; 137(11): 2456 - 2463. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M Pfeiffer, C. L Johnson, R. B Jain, E. A Yetley, M. F. Picciano, J. I Rader, K. D Fisher, J. Mulinare, and J. D Osterloh Trends in blood folate and vitamin B-12 concentrations in the United States, 1988 2004 Am. J. Clinical Nutrition, September 1, 2007; 86(3): 718 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. M Ulrich Folate and cancer prevention: a closer look at a complex picture Am. J. Clinical Nutrition, August 1, 2007; 86(2): 271 - 273. [Full Text] [PDF]
|
|
|
|
|
|
A D. Smith Reply to RJ Berry et al Am. J. Clinical Nutrition, July 1, 2007; 86(1): 268 - 269. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Chattopadhyay, R. Tamari, S. H. Min, R. Zhao, E. Tsai, and I. D. Goldman Commentary: A Case for Minimizing Folate Supplementation in Clinical Regimens with Pemetrexed Based on the Marked Sensitivity of the Drug to Folate Availability Oncologist, July 1, 2007; 12(7): 808 - 815. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Q.-H. Yang, H. K Carter, J. Mulinare, R. Berry, J. Friedman, and J D. Erickson Race-ethnicity differences in folic acid intake in women of childbearing age in the United States after folic acid fortification: findings from the National Health and Nutrition Examination Survey, 2001-2002 Am. J. Clinical Nutrition, May 1, 2007; 85(5): 1409 - 1416. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-K. Kuo, K.-C. Liao, S. G. Leveille, J. F. Bean, C.-J. Yen, J.-H. Chen, Y.-H. Yu, and T.-Y. Tai Relationship of Homocysteine Levels to Quadriceps Strength, Gait Speed, and Late-Life Disability in Older Adults J. Gerontol. A Biol. Sci. Med. Sci., April 1, 2007; 62(4): 434 - 439. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z. Fazili, C. M. Pfeiffer, and M. Zhang Comparison of Serum Folate Species Analyzed by LC-MS/MS with Total Folate Measured by Microbiologic Assay and Bio-Rad Radioassay Clin. Chem., April 1, 2007; 53(4): 781 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. D Stark, R. J Pawlosky, R. J Sokol, J. H Hannigan, and N. Salem Jr Maternal smoking is associated with decreased 5-methyltetrahydrofolate in cord plasma Am. J. Clinical Nutrition, March 1, 2007; 85(3): 796 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A D. Smith Folic acid fortification: the good, the bad, and the puzzle of vitamin B-12 Am. J. Clinical Nutrition, January 1, 2007; 85(1): 3 - 5. [Full Text] [PDF]
|
|
|
|
|
|
M. S. Morris, P. F Jacques, I. H Rosenberg, and J. Selhub Folate and vitamin B-12 status in relation to anemia, macrocytosis, and cognitive impairment in older Americans in the age of folic acid fortification Am. J. Clinical Nutrition, January 1, 2007; 85(1): 193 - 200. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Poo-Prieto, D. B. Haytowitz, J. M. Holden, G. Rogers, S. F. Choumenkovitch, P. F. Jacques, and J. Selhub Use of the Affinity/HPLC Method for Quantitative Estimation of Folic Acid in Enriched Cereal-Grain Products J. Nutr., December 1, 2006; 136(12): 3079 - 3083. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. G.K. Bentley, W. C. Willett, M. C. Weinstein, and K. M. Kuntz Population-Level Changes in Folate Intake by Age, Gender, and Race/Ethnicity after Folic Acid Fortification Am J Public Health, November 1, 2006; 96(11): 2040 - 2047. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Clarke Vitamin B12, folic acid, and the prevention of dementia. N. Engl. J. Med., June 29, 2006; 354(26): 2817 - 2819. [Full Text] [PDF]
|
|
|
|
|
|
L. A Houghton, K. L Sherwood, R. Pawlosky, S. Ito, and D. L O'Connor [6S]-5-Methyltetrahydrofolate is at least as effective as folic acid in preventing a decline in blood folate concentrations during lactation. Am. J. Clinical Nutrition, April 1, 2006; 83(4): 842 - 850. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. I. Rader and B. O. Schneeman Prevalence of Neural Tube Defects, Folate Status, and Folate Fortification of Enriched Cereal-Grain Products in the United States Pediatrics, April 1, 2006; 117(4): 1394 - 1399. [Full Text] [PDF]
|
|
|
|
|
|
C. M. Ulrich and J. D. Potter Folate supplementation: too much of a good thing? Cancer Epidemiol. Biomarkers Prev., February 1, 2006; 15(2): 189 - 193. [Full Text] [PDF]
|
|
|
|
|
|
B. Beagle, T. L. Yang, J. Hung, E. A. Cogger, D. J. Moriarty, and M. A. Caudill The Glycine N-Methyltransferase (GNMT) 1289 C->T Variant Influences Plasma Total Homocysteine Concentrations in Young Women after Restricting Folate Intake J. Nutr., December 1, 2005; 135(12): 2780 - 2785. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. H Rosenberg Science-based micronutrient fortification: which nutrients, how much, and how to know? Am. J. Clinical Nutrition, August 1, 2005; 82(2): 279 - 280. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
) and females (
) and for persons aged 
). Vitamin B-12 was measured only during 1991–1994.